MedTrace Logo

A Study With CIT-013 in HS Patients

NCT06993233 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2026-05-22

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if CIT-013 works to treat Hidradenitis Suppurativa in adults. It will also learn about the safety of CIT-013. The main questions it aims to answer are:

Does CIT-013 lower the disease activity of HS patients? What medical problems do participants have when receiving CIT-013? Researchers will compare CIT-013 to a placebo (a look-alike substance that contains no drug) to see if CIT-013 works to treat the symptoms of HS.

Participants will:

Take receive 50 or 100 mg CIT-013 or placebo every other week for 12 weeks Visit the clinic once every 2 weeks for checkups and tests Keep monitor their symptoms during this period

Conditions

  • Hidradenitis Suppurativa (HS)

Interventions

DRUG

CIT-013 high dose

subcutaneous injection

DRUG

CIT-013 medium dose

subcutaneous injection

DRUG

Placebo

subcutaneous injection

Sponsors & Collaborators

  • Citryll BV

    lead INDUSTRY

Principal Investigators

  • Maarten Kraan · Citryll BV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-31
Primary Completion
2027-04-30
Completion
2027-07-31

Countries

  • Canada
  • Germany
  • Netherlands
  • Poland
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06993233 on ClinicalTrials.gov